Group 1 - As of August 4, 2025, Zhongheng Group's stock price is 2.74 yuan, down 0.02 yuan or 0.72% from the previous trading day [1] - The trading volume for the day was 616,400 hands, with a total transaction amount of 166.7 million yuan [1] - Zhongheng Group primarily engages in pharmaceutical manufacturing, with core products including thrombolytic agents for cardiovascular diseases [1] Group 2 - The company has a wholly-owned subsidiary, Zhongheng Innovation, which acquired a patent for a drug treating chronic heart failure for 55 million yuan [1] - This drug is a novel compound discovered by the Navy Medical University, significantly enhancing myocardial energy metabolism, and currently, there are no similar drugs on the market globally [1] - The company operates in various sectors, including pharmaceutical manufacturing, research and development, and health food, making it a key player in the Guangxi region [1]

格隆汇8月4日丨中恒集团(600252.SH)公布，为契合公司发展战略，持续优化与延伸产品管线，公司全 资子公司中恒创新拟受让取得中国人民解放军海军军医大学持有的一种治疗慢性心力衰竭的药物技术 （专利权）。根据上海技术交易所2025年5月20日发布的挂牌公告，该项目挂牌转让底价为人民币 5,500.00万元，保证金为人民币50.00万元，本次转让挂牌结束日期为2025年6月18日。该项目的转让总 价由首付款与里程碑付款构成。其中，首付款不少于500.00万元，需于《技术（专利权）转让合同》生 效之日起10个工作日内支付至转让方指定银行账户，后续里程碑付款在相对应的里程碑事件发生后10个 工作日内予以支付；具体节点与条件以合同约定为准。2025年6月20日，中恒创新收到上海技术交易所 出具的《受让资格确认通知书》《组织签约通知》，确认中恒创新为"一种治疗慢性心力衰竭的药物"的 受让方。成交价格为人民币5,500.00万元。2025年8月1日，中恒创新与中国融通科研院签订《技术（专 利权）转让合同》。 ...